Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes
ConclusionsWe determined that uterine carcinosarcoma, synovial sarcoma, and leiomyosarcoma patients would potentially benefit from PRAME-specific immunotherapies. Tumor escape through loss of antigen presentation needs to be further studied.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer of the Uterus | Carcinosarcoma | Genetics | Immunotherapy | Leiomyosarcoma | Melanoma | Sarcomas | Skin Cancer | Synovial Sarcoma